NCT05198843
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer (IBC)
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have metastases accessible for biopsy
Exclusions: Patients without one standard regimen exposure in a metastatic setting; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05198843